In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Feature|Articles|July 6, 2026
Polyendocrine metabolic ovarian syndrome: looking past the reproductive system to the eye
Author(s)Lynda Charters
Fact checked by: Katherine Talcott, MD
Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.
Advertisement
Advertisement
Polycystic ovarian syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS),1is the most common endocrine disorder among females of reproductive age worldwide,2 affecting from 4% to 20% of women.3
Related to this article
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.
The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Length and width, not thickness, emerge as key drivers of higher-order aberrations.
Advertisement
Advertisement